Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-claudin18.2 monoclonal antibody AB011

A recombinant humanized monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-claudin18.2 monoclonal antibody AB011 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CLDN18.2 monoclonal antibody AB011
Code name:AB 011
AB-011
AB011
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search